Company profile

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Privately held: no public share price (An operating subsidiary of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (already resolved in the existing roster as company_id 1518, itself part of Sino Biopharmaceutical, HKEX:1177); the subsidiary itself is not separately listed. GLEIF suggestions returned were unrelated fuzzy name matches, not used. Sources: https://clinicaltrials.gov/study/NCT06700395 Entity resolved by asset-pipeline-v2.)

Assets

(4 total)

4Total Assets

0Approved

2Phase 3 / Filed

2Phase 1–2 / Early

3Diseases

Showing 4 of 4 assets

		Target & Modality
TQB2102	Phase 3	HER2Antibody–drug conjugate	Non-Small Cell Lung Cancer
TQH2722	Phase 3	IL-4R-alphaMonoclonal antibody	Atopic Dermatitis
TQB2029	Phase 1	GPRC5D x CD3Multispecific antibody	Multiple Myeloma
TQB2928	Phase 1	CD47/SIRPα (SIRPa) interaction	Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.